ID   KPCB_HUMAN              Reviewed;         671 AA.
AC   P05771; C5IFJ8; D3DWF5; O43744; P05127; Q15138; Q93060; Q9UE49;
AC   Q9UE50; Q9UEH8; Q9UJ30; Q9UJ33;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 4.
DT   12-APR-2017, entry version 217.
DE   RecName: Full=Protein kinase C beta type;
DE            Short=PKC-B;
DE            Short=PKC-beta;
DE            EC=2.7.11.13;
GN   Name=PRKCB; Synonyms=PKCB, PRKCB1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA-II).
RX   PubMed=3755548; DOI=10.1126/science.3755548;
RA   Coussens L., Parker P.J., Rhee L., Yang-Feng T.L., Chen E.,
RA   Waterfield M.D., Francke U., Ullrich A.;
RT   "Multiple, distinct forms of bovine and human protein kinase C suggest
RT   diversity in cellular signaling pathways.";
RL   Science 233:859-866(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS BETA-I AND BETA-II).
RX   PubMed=3666134; DOI=10.1016/0014-5793(87)80524-0;
RA   Kubo K., Ohno S., Suzuki K.;
RT   "Primary structures of human protein kinase C beta I and beta II
RT   differ only in their C-terminal sequences.";
RL   FEBS Lett. 223:138-142(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2009) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=10493829; DOI=10.1006/geno.1999.5927;
RA   Loftus B.J., Kim U.-J., Sneddon V.P., Kalush F., Brandon R.,
RA   Fuhrmann J., Mason T., Crosby M.L., Barnstead M., Cronin L.,
RA   Mays A.D., Cao Y., Xu R.X., Kang H.-L., Mitchell S., Eichler E.E.,
RA   Harris P.C., Venter J.C., Adams M.D.;
RT   "Genome duplications and other features in 12 Mb of DNA sequence from
RT   human chromosome 16p and 16q.";
RL   Genomics 60:295-308(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Hippocampus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-69.
RX   PubMed=7880442; DOI=10.1089/dna.1995.14.213;
RA   Mahajna J., King P., Parker P., Haley J.;
RT   "Autoregulation of cloned human protein kinase C beta and gamma gene
RT   promoters in U937 cells.";
RL   DNA Cell Biol. 14:213-222(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58.
RX   PubMed=1556124;
RA   Niino Y.S., Ohno S., Suzuki K.;
RT   "Positive and negative regulation of the transcription of the human
RT   protein kinase C beta gene.";
RL   J. Biol. Chem. 267:6158-6163(1992).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57.
RX   PubMed=1400396;
RA   Obeid L.M., Blobe G.C., Karolak L.A., Hannun Y.A.;
RT   "Cloning and characterization of the major promoter of the human
RT   protein kinase C beta gene. Regulation by phorbol esters.";
RL   J. Biol. Chem. 267:20804-20810(1992).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-19, AND ACETYLATION AT ALA-2.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 97-176.
RA   Greenham J.A., Adams M.D., Doggett N.A., Mole S.E.;
RT   "The genomic structure of the human protein kinase C beta gene
RT   (PRKCB).";
RL   Submitted (NOV-1997) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 609-671.
RC   TISSUE=Fetal brain;
RX   PubMed=3677994; DOI=10.1089/dna.1987.6.389;
RA   Coussens L., Rhee L., Parker P.J., Ullrich A.;
RT   "Alternative splicing increases the diversity of the human protein
RT   kinase C family.";
RL   DNA 6:389-394(1987).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 622-671.
RX   PubMed=3658678; DOI=10.1093/nar/15.17.7179;
RA   Kubo K., Ohno S., Suzuki K.;
RT   "Nucleotide sequence of the 3' portion of a human gene for protein
RT   kinase C beta-I/beta-II.";
RL   Nucleic Acids Res. 15:7179-7180(1987).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF BTK.
RX   PubMed=11598012; DOI=10.1093/emboj/20.20.5692;
RA   Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M.,
RA   Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N.,
RA   Rawlings D.J.;
RT   "PKCbeta modulates antigen receptor signaling via regulation of Btk
RT   membrane localization.";
RL   EMBO J. 20:5692-5702(2001).
RN   [15]
RP   ENZYME REGULATION.
RX   PubMed=16103100; DOI=10.1158/0008-5472.CAN-05-0071;
RA   Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L.,
RA   Bailey S.N., Banks C., Capen A., Goode R., Lewis J.E., Sams L.,
RA   Huss K.L., Campbell R.M., Iversen P.W., Neubauer B.L., Brown T.J.,
RA   Musib L., Geeganage S., Thornton D.;
RT   "The protein kinase Cbeta-selective inhibitor, enzastaurin
RT   (LY317615.HCl), suppresses signaling through the AKT pathway, induces
RT   apoptosis, and suppresses growth of human colon cancer and
RT   glioblastoma xenografts.";
RL   Cancer Res. 65:7462-7469(2005).
RN   [16]
RP   INTERACTION WITH PHLPP1 AND PHLPP2.
RX   PubMed=18162466; DOI=10.1074/jbc.M707319200;
RA   Gao T., Brognard J., Newton A.C.;
RT   "The phosphatase PHLPP controls the cellular levels of protein kinase
RT   C.";
RL   J. Biol. Chem. 283:6300-6311(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [18]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.M808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of
RT   transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-504, PHOSPHORYLATION
RP   [LARGE SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM BETA-II), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [20]
RP   FUNCTION IN HISTONE H3 PHOSPHORYLATION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH KDM1A; PKN1 AND ANDR.
RX   PubMed=20228790; DOI=10.1038/nature08839;
RA   Metzger E., Imhof A., Patel D., Kahl P., Hoffmeyer K., Friedrichs N.,
RA   Muller J.M., Greschik H., Kirfel J., Ji S., Kunowska N.,
RA   Beisenherz-Huss C., Gunther T., Buettner R., Schule R.;
RT   "Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation
RT   at histone H3K4.";
RL   Nature 464:792-796(2010).
RN   [21]
RP   REVIEW ON FUNCTION.
RX   PubMed=12417015; DOI=10.1093/oxfordjournals.jbchem.a003273;
RA   Kawakami T., Kawakami Y., Kitaura J.;
RT   "Protein kinase C beta (PKC beta): normal functions and diseases.";
RL   J. Biochem. 132:677-682(2002).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=20186491; DOI=10.1007/s11154-010-9134-4;
RA   Tabit C.E., Chung W.B., Hamburg N.M., Vita J.A.;
RT   "Endothelial dysfunction in diabetes mellitus: molecular mechanisms
RT   and clinical implications.";
RL   Rev. Endocr. Metab. Disord. 11:61-74(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-11; THR-17; SER-206;
RP   SER-311; THR-314 AND THR-642, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-641 AND SER-660 (ISOFORM
RP   BETA-II), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 321-660 IN COMPLEX WITH
RP   INHIBITOR, AND PHOSPHORYLATION AT THR-500; THR-642 AND SER-661.
RX   PubMed=17115692; DOI=10.1021/bi061128h;
RA   Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B.,
RA   Nonomiya J., Grant S.;
RT   "Structure of the catalytic domain of human protein kinase C beta II
RT   complexed with a bisindolylmaleimide inhibitor.";
RL   Biochemistry 45:13970-13981(2006).
RN   [27]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-144; MET-496 AND HIS-588.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase involved in
CC       various cellular processes such as regulation of the B-cell
CC       receptor (BCR) signalosome, oxidative stress-induced apoptosis,
CC       androgen receptor-dependent transcription regulation, insulin
CC       signaling and endothelial cells proliferation. Plays a key role in
CC       B-cell activation by regulating BCR-induced NF-kappa-B activation.
CC       Mediates the activation of the canonical NF-kappa-B pathway
CC       (NFKB1) by direct phosphorylation of CARD11/CARMA1 at 'Ser-559',
CC       'Ser-644' and 'Ser-652'. Phosphorylation induces CARD11/CARMA1
CC       association with lipid rafts and recruitment of the BCL10-MALT1
CC       complex as well as MAP3K7/TAK1, which then activates IKK complex,
CC       resulting in nuclear translocation and activation of NFKB1. Plays
CC       a direct role in the negative feedback regulation of the BCR
CC       signaling, by down-modulating BTK function via direct
CC       phosphorylation of BTK at 'Ser-180', which results in the
CC       alteration of BTK plasma membrane localization and in turn
CC       inhibition of BTK activity. Involved in apoptosis following
CC       oxidative damage: in case of oxidative conditions, specifically
CC       phosphorylates 'Ser-36' of isoform p66Shc of SHC1, leading to
CC       mitochondrial accumulation of p66Shc, where p66Shc acts as a
CC       reactive oxygen species producer. Acts as a coactivator of
CC       androgen receptor (ANDR)-dependent transcription, by being
CC       recruited to ANDR target genes and specifically mediating
CC       phosphorylation of 'Thr-6' of histone H3 (H3T6ph), a specific tag
CC       for epigenetic transcriptional activation that prevents
CC       demethylation of histone H3 'Lys-4' (H3K4me) by LSD1/KDM1A. In
CC       insulin signaling, may function downstream of IRS1 in muscle cells
CC       and mediate insulin-dependent DNA synthesis through the RAF1-
CC       MAPK/ERK signaling cascade. May participate in the regulation of
CC       glucose transport in adipocytes by negatively modulating the
CC       insulin-stimulated translocation of the glucose transporter
CC       SLC2A4/GLUT4. Under high glucose in pancreatic beta-cells, is
CC       probably involved in the inhibition of the insulin gene
CC       transcription, via regulation of MYC expression. In endothelial
CC       cells, activation of PRKCB induces increased phosphorylation of
CC       RB1, increased VEGFA-induced cell proliferation, and inhibits
CC       PI3K/AKT-dependent nitric oxide synthase (NOS3/eNOS) regulation by
CC       insulin, which causes endothelial dysfunction. Also involved in
CC       triglyceride homeostasis (By similarity). Phosphorylates ATF2
CC       which promotes cooperation between ATF2 and JUN, activating
CC       transcription. {ECO:0000250, ECO:0000269|PubMed:11598012,
CC       ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:20228790}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:20228790}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000250|UniProtKB:P68403};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000250|UniProtKB:P68403};
CC   -!- ENZYME REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB
CC       and PRKCG) are activated by calcium and diacylglycerol (DAG) in
CC       the presence of phosphatidylserine. Three specific sites; Thr-500
CC       (activation loop of the kinase domain), Thr-642 (turn motif) and
CC       Ser-661 (hydrophobic region), need to be phosphorylated for its
CC       full activation. Specifically inhibited by enzastaurin (LY317615).
CC       {ECO:0000269|PubMed:16103100}.
CC   -!- SUBUNIT: Interacts with PDK1 (By similarity). Interacts in vitro
CC       with PRKCBP1. Interacts with PHLPP1 and PHLPP2; both proteins
CC       mediate its dephosphorylation. Interacts with KDM1A/LSD1, PKN1 and
CC       ANDR. {ECO:0000250, ECO:0000269|PubMed:17115692,
CC       ECO:0000269|PubMed:18162466, ECO:0000269|PubMed:20228790}.
CC   -!- INTERACTION:
CC       O60346:PHLPP1; NbExp=5; IntAct=EBI-5774511, EBI-2511516;
CC       Q8NEM2:SHCBP1; NbExp=2; IntAct=EBI-706216, EBI-744700;
CC       Q9BSI4:TINF2; NbExp=2; IntAct=EBI-706216, EBI-717399;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:20228790}. Membrane {ECO:0000250}; Peripheral
CC       membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Beta-I; Synonyms=PRKCB1;
CC         IsoId=P05771-1; Sequence=Displayed;
CC       Name=Beta-II; Synonyms=PRKCB2;
CC         IsoId=P05771-2; Sequence=VSP_004738;
CC         Note=Contains a phosphoserine at position 660. Contains a
CC         phosphothreonine at position 641. {ECO:0000244|PubMed:19369195,
CC         ECO:0000244|PubMed:24275569};
CC   -!- PTM: Phosphorylation on Thr-500 within the activation loop renders
CC       it competent to autophosphorylate. Subsequent autophosphorylation
CC       of Thr-642 maintains catalytic competence, and autophosphorylation
CC       on Ser-661 appears to release the kinase into the cytosol.
CC       Autophosphorylation on other sites i.e. in the N-terminal and
CC       hinge regions have no effect on enzyme activity. Phosphorylation
CC       at Tyr-662 by SYK induces binding with GRB2 and contributes to the
CC       activation of MAPK/ERK signaling cascade (By similarity).
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkcb1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M13975; AAA60095.1; -; mRNA.
DR   EMBL; X06318; CAA29634.1; -; mRNA.
DR   EMBL; X07109; CAA30130.1; -; mRNA.
DR   EMBL; FJ907246; ACS14045.1; -; Genomic_DNA.
DR   EMBL; AC130454; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC002299; AAB97933.1; -; Genomic_DNA.
DR   EMBL; AC002299; AAB97934.1; -; Genomic_DNA.
DR   EMBL; CH471145; EAW55797.1; -; Genomic_DNA.
DR   EMBL; CH471145; EAW55798.1; -; Genomic_DNA.
DR   EMBL; BC036472; AAH36472.1; -; mRNA.
DR   EMBL; X62532; CAA44393.1; -; Genomic_DNA.
DR   EMBL; S47311; AAD13852.1; -; Genomic_DNA.
DR   EMBL; D10022; BAA00912.1; -; Genomic_DNA.
DR   EMBL; AJ002799; CAA05725.1; -; Genomic_DNA.
DR   EMBL; AJ002800; CAA05725.1; JOINED; Genomic_DNA.
DR   EMBL; M18254; AAA60096.1; -; Genomic_DNA.
DR   EMBL; M18255; AAA60097.1; -; Genomic_DNA.
DR   EMBL; X05972; CAA29396.1; -; Genomic_DNA.
DR   EMBL; X05971; CAA29395.1; -; Genomic_DNA.
DR   CCDS; CCDS10618.1; -. [P05771-1]
DR   CCDS; CCDS10619.1; -. [P05771-2]
DR   PIR; B24664; KIHUC2.
DR   PIR; S00159; KIHUC1.
DR   RefSeq; NP_002729.2; NM_002738.6. [P05771-2]
DR   RefSeq; NP_997700.1; NM_212535.2. [P05771-1]
DR   UniGene; Hs.460355; -.
DR   PDB; 2I0E; X-ray; 2.60 A; A/B=321-671.
DR   PDBsum; 2I0E; -.
DR   ProteinModelPortal; P05771; -.
DR   SMR; P05771; -.
DR   BioGrid; 111565; 65.
DR   DIP; DIP-34187N; -.
DR   IntAct; P05771; 22.
DR   MINT; MINT-240997; -.
DR   STRING; 9606.ENSP00000305355; -.
DR   BindingDB; P05771; -.
DR   ChEMBL; CHEMBL3045; -.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB01738; O-Phosphoethanolamine.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00163; Vitamin E.
DR   GuidetoPHARMACOLOGY; 1483; -.
DR   iPTMnet; P05771; -.
DR   PhosphoSitePlus; P05771; -.
DR   BioMuta; PRKCB; -.
DR   DMDM; 20141488; -.
DR   MaxQB; P05771; -.
DR   PaxDb; P05771; -.
DR   PeptideAtlas; P05771; -.
DR   PRIDE; P05771; -.
DR   DNASU; 5579; -.
DR   Ensembl; ENST00000303531; ENSP00000305355; ENSG00000166501. [P05771-2]
DR   Ensembl; ENST00000321728; ENSP00000318315; ENSG00000166501. [P05771-1]
DR   GeneID; 5579; -.
DR   KEGG; hsa:5579; -.
DR   UCSC; uc002dmd.4; human. [P05771-1]
DR   CTD; 5579; -.
DR   DisGeNET; 5579; -.
DR   GeneCards; PRKCB; -.
DR   HGNC; HGNC:9395; PRKCB.
DR   HPA; CAB003843; -.
DR   HPA; HPA048321; -.
DR   HPA; HPA054203; -.
DR   MIM; 176970; gene.
DR   neXtProt; NX_P05771; -.
DR   OpenTargets; ENSG00000166501; -.
DR   PharmGKB; PA33761; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P05771; -.
DR   KO; K19662; -.
DR   OMA; QAHIDRE; -.
DR   OrthoDB; EOG091G0QRS; -.
DR   PhylomeDB; P05771; -.
DR   TreeFam; TF351133; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-114516; Disinhibition of SNARE formation.
DR   Reactome; R-HSA-1169091; Activation of NF-kappaB in B cells.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-4419969; Depolymerisation of the Nuclear Lamina.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+.
DR   SABIO-RK; P05771; -.
DR   SignaLink; P05771; -.
DR   SIGNOR; P05771; -.
DR   ChiTaRS; PRKCB; human.
DR   EvolutionaryTrace; P05771; -.
DR   GeneWiki; PRKCB1; -.
DR   GenomeRNAi; 5579; -.
DR   PMAP-CutDB; P05771; -.
DR   PRO; PR:P05771; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000166501; -.
DR   ExpressionAtlas; P05771; baseline and differential.
DR   Genevisible; P05771; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0050681; F:androgen receptor binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005246; F:calcium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; TAS:Reactome.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0035403; F:histone kinase activity (H3-T6 specific); IDA:UniProtKB.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IMP:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; TAS:Reactome.
DR   GO; GO:0005080; F:protein kinase C binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0042113; P:B cell activation; ISS:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071322; P:cellular response to carbohydrate stimulus; IEA:Ensembl.
DR   GO; GO:0035408; P:histone H3-T6 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0042953; P:lipoprotein transport; TAS:BHF-UCL.
DR   GO; GO:0007077; P:mitotic nuclear envelope disassembly; TAS:Reactome.
DR   GO; GO:0010829; P:negative regulation of glucose transport; ISS:UniProtKB.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0050861; P:positive regulation of B cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0030949; P:positive regulation of vascular endothelial growth factor receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; NAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05616; STKc_cPKC_beta; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR034664; cPKC_beta.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   Apoptosis; ATP-binding; Calcium; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Direct protein sequencing; Immunity;
KW   Kinase; Membrane; Metal-binding; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:12665801}.
FT   CHAIN         2    671       Protein kinase C beta type.
FT                                /FTId=PRO_0000055684.
FT   DOMAIN      173    260       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      342    600       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      601    671       AGC-kinase C-terminal.
FT   ZN_FING      36     86       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     101    151       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     348    356       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    466    466       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL       186    186       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       187    187       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       187    187       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       193    193       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       246    246       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       246    246       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       247    247       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       248    248       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       248    248       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       248    248       Calcium 3.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       251    251       Calcium 3.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       252    252       Calcium 3; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       254    254       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   METAL       254    254       Calcium 3.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   BINDING     371    371       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:12665801}.
FT   MOD_RES      11     11       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES      16     16       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P68403,
FT                                ECO:0000255}.
FT   MOD_RES      17     17       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     206    206       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     250    250       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     311    311       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     314    314       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     322    322       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P63318}.
FT   MOD_RES     324    324       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P68403,
FT                                ECO:0000255}.
FT   MOD_RES     500    500       Phosphothreonine; by PDPK1.
FT                                {ECO:0000305|PubMed:17115692}.
FT   MOD_RES     504    504       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES     635    635       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P68403}.
FT   MOD_RES     642    642       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17115692}.
FT   MOD_RES     661    661       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:17115692}.
FT   MOD_RES     662    662       Phosphotyrosine; by SYK. {ECO:0000250}.
FT   VAR_SEQ     622    671       RDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGFSY
FT                                TNPEFVINV -> CGRNAENFDRFFTRHPPVLTPPDQEVIR
FT                                NIDQSEFEGFSFVNSEFLKPEVKS (in isoform
FT                                Beta-II). {ECO:0000303|PubMed:3666134,
FT                                ECO:0000303|PubMed:3755548}.
FT                                /FTId=VSP_004738.
FT   VARIANT     144    144       V -> M (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs764534677).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042304.
FT   VARIANT     496    496       V -> M (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042305.
FT   VARIANT     588    588       P -> H (in dbSNP:rs35631544).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042306.
FT   CONFLICT     69     69       V -> G (in Ref. 7; CAA44393).
FT                                {ECO:0000305}.
FT   STRAND      342    351       {ECO:0000244|PDB:2I0E}.
FT   STRAND      354    361       {ECO:0000244|PDB:2I0E}.
FT   STRAND      364    374       {ECO:0000244|PDB:2I0E}.
FT   HELIX       375    380       {ECO:0000244|PDB:2I0E}.
FT   HELIX       384    394       {ECO:0000244|PDB:2I0E}.
FT   STRAND      406    411       {ECO:0000244|PDB:2I0E}.
FT   STRAND      413    421       {ECO:0000244|PDB:2I0E}.
FT   HELIX       428    435       {ECO:0000244|PDB:2I0E}.
FT   HELIX       440    459       {ECO:0000244|PDB:2I0E}.
FT   HELIX       469    471       {ECO:0000244|PDB:2I0E}.
FT   STRAND      472    474       {ECO:0000244|PDB:2I0E}.
FT   STRAND      480    482       {ECO:0000244|PDB:2I0E}.
FT   HELIX       505    507       {ECO:0000244|PDB:2I0E}.
FT   HELIX       510    513       {ECO:0000244|PDB:2I0E}.
FT   HELIX       521    536       {ECO:0000244|PDB:2I0E}.
FT   HELIX       546    555       {ECO:0000244|PDB:2I0E}.
FT   HELIX       566    575       {ECO:0000244|PDB:2I0E}.
FT   HELIX       590    595       {ECO:0000244|PDB:2I0E}.
FT   HELIX       598    600       {ECO:0000244|PDB:2I0E}.
FT   HELIX       605    609       {ECO:0000244|PDB:2I0E}.
FT   HELIX       629    636       {ECO:0000244|PDB:2I0E}.
FT   TURN        654    657       {ECO:0000244|PDB:2I0E}.
SQ   SEQUENCE   671 AA;  76869 MW;  3937E7B667108C68 CRC64;
     MADPAAGPPP SEGEESTVRF ARKGALRQKN VHEVKNHKFT ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPASDDPRS KHKFKIHTYS SPTFCDHCGS
     LLYGLIHQGM KCDTCMMNVH KRCVMNVPSL CGTDHTERRG RIYIQAHIDR DVLIVLVRDA
     KNLVPMDPNG LSDPYVKLKL IPDPKSESKQ KTKTIKCSLN PEWNETFRFQ LKESDKDRRL
     SVEIWDWDLT SRNDFMGSLS FGISELQKAS VDGWFKLLSQ EEGEYFNVPV PPEGSEANEE
     LRQKFERAKI SQGTKVPEEK TTNTVSKFDN NGNRDRMKLT DFNFLMVLGK GSFGKVMLSE
     RKGTDELYAV KILKKDVVIQ DDDVECTMVE KRVLALPGKP PFLTQLHSCF QTMDRLYFVM
     EYVNGGDLMY HIQQVGRFKE PHAVFYAAEI AIGLFFLQSK GIIYRDLKLD NVMLDSEGHI
     KIADFGMCKE NIWDGVTTKT FCGTPDYIAP EIIAYQPYGK SVDWWAFGVL LYEMLAGQAP
     FEGEDEDELF QSIMEHNVAY PKSMSKEAVA ICKGLMTKHP GKRLGCGPEG ERDIKEHAFF
     RYIDWEKLER KEIQPPYKPK ARDKRDTSNF DKEFTRQPVE LTPTDKLFIM NLDQNEFAGF
     SYTNPEFVIN V
//
